Biogen scores Cannes Festival win with dark humored campaign

The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

By Alexandra Pecci • June 24, 2025

How a patient group tackled research diversity for one disease and triggered change for pharma

A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

By Meagan Parrish • June 17, 2025

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Will pharma finally score a policy win for 340B?

The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

By Kelly Bilodeau • June 16, 2025

A day in the life of GSK’s U.S. president

How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.

By Meagan Parrish • June 13, 2025

COVID vax restrictions may not hamper uptake — but the market is still under pressure

If insurers stop covering the shots and approvals become more restrictive, the most recent policy shifts could heap more challenges onto pharma’s vaccine space. 

By Alexandra Pecci • June 10, 2025

AbbVie’s ADC win shows how pharma can break through in solid tumors

 An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.

By Meagan Parrish • May 30, 2025

Beyond the drug: Closing the knowledge gap for injectable diabetes meds

As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most out of injectable drugs. 

By Michael Gibney • April 22, 2025

Genetic breakthroughs could point pharma to a long COVID drug

The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.

By Kelly Bilodeau • April 22, 2025

The fallout from UnitedHealth’s CEO slaying

Brian Thompson’s murder has raised questions about the cost of U.S. healthcare, embroiling insurers, drugmakers and PBMs in a battle for the future of the industry.

By PharmaVoice staff • April 15, 2025

Her son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.

Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.

By Michael Gibney • April 8, 2025

A birth control pill for men makes moves in the clinic

So far, the science and safety seem solid. But is the world emotionally ready to shift the responsibility of contraception to men?

By Kelly Bilodeau • April 7, 2025

With government health info in limbo, drugmakers lose credible sources

The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.

By Alexandra Pecci • April 1, 2025

A recent gene therapy death shines a light on AAV safety

This technology brings both benefits and drawbacks for the field, which is also testing alternatives.

By Kelly Bilodeau • March 31, 2025

FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.

The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.

By Meagan Parrish • March 28, 2025

Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.

By Michael Gibney • March 20, 2025

Pricing transparency is in the spotlight — and that could be good news for drugmakers

An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?

By Michael Gibney • March 11, 2025

Navigating human errors in medical device usage: Insights from human factors research

Even the most advanced medical devices can fail patients if used incorrectly. These are the most common errors.

By Samantha Colangelo, M.S. • March 10, 2025

The top 3 impacts of Trump’s health data purge

Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.

By Michael Brady • March 6, 2025

Americans want to participate in clinical trials — so why don’t they?

A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.

By Kelly Bilodeau • March 4, 2025

Transforming biopharma’s approach to patient engagement with direct-to-patient programs

Consumers want more from biopharma. Next-generation direct-to-patient programs can deliver.

By Matthew Walsh, General Manager, Biopharma, ixlayer • March 3, 2025

Teva targets schizophrenia to build on innovative medicines growth

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

By Meagan Parrish • Feb. 28, 2025

Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

By Michael Gibney • Feb. 25, 2025

In FDA job cuts, experts see threat of far-reaching impact

"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.

By Jonathan Gardner , Delilah Alvarado • Feb. 21, 2025

The kids are alright: How pharma can make inroads with Gen Z

As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.

By Amy Baxter • Feb. 12, 2025

Are orexins the next golden child of neuroscience?

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

By Meagan Parrish • Feb. 10, 2025